4.5 Review

Radiomics and radiogenomics in lung cancer: A review for the clinician

期刊

LUNG CANCER
卷 115, 期 -, 页码 34-41

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.10.015

关键词

Radiomics; Radiogenomics; Image analysis; Lung cancer

资金

  1. Genentech
  2. Trovagene
  3. Eisai
  4. OncoPlex Diagnostics
  5. Alkermes
  6. NantOmics
  7. Genoptix
  8. Altor BioScience
  9. Merck
  10. Bristol-Myers Squibb
  11. Atreca
  12. Heat Biologics
  13. Leap Therapeutics
  14. PathCore Inc.

向作者/读者索取更多资源

Lung cancer is responsible for a large proportion of cancer-related deaths across the globe, with delayed detection being perhaps the most significant factor for its high mortality rate. Though the National Lung Screening Trial argues for screening of certain at-risk populations, the practical implementation of these screening efforts has not yet been successful and remains in high demand. Radiomics refers to the computerized extraction of data from radiologic images, and provides unique potential for making lung cancer screening more rapid and accurate using machine learning algorithms. The quantitative features analyzed express subvisual characteristics of images which correlate with pathogenesis of diseases. These features are broadly classified into four categories: intensity, structure, texture/gradient, and wavelet, based on the types of image attributes they capture. Many studies have been done to show correlation between these features and the malignant potential of a nodule on a chest CT. In cancer patients, these nodules also have features that can be correlated with prognosis and mutation status. The major limitations of radiomics are the lack of standardization of acquisition parameters, inconsistent radiomic methods, and lack of reproducibility. Researchers are working on overcoming these limitations, which would make radiomics more acceptable in the medical community.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据